ALXN News and Press, Alexion Pharmaceuticals Inc. From 03/11/19

Sell-Off in Biotech-Land Last week, biotechs were blindsided Tuesday when it was announced that FDA Commissioner Scott Gottlieb will be resigning imminently. A broad index of biotech stocks ((BTK)) - not an ETF (which is managed) - dropped from an intra-day high of 5,123 to close the week ne...

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Cowen 39 th Annual Health Care Conference in Boston, MA on Tuesday, March 12, 2019 at 11:20 a.m., ET. An audio webcast of the presentation will be available live. You can access the webcast at: h...

The FDA accepts under Priority Review Alexion Pharmaceuticals' ( ALXN +1% ) supplemental marketing application seeking approval to use Soliris (eculizumab) to treat patients with neuromyelitis optica spectrum disorder (NMOSD) who have anti-aquaporin-4 (AQP4) autoantibodies (antibodies di...

FDA sets action date of June 28, 2019 Filing in the European Union under review, and filing in Japan planned for Q1 2019 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics...

Alexion Pharmaceuticals (NASDAQ: ALXN ) initiated with Neutral rating and $135 (6% upside) price target at Guggenheim. More news on: Alexion Pharmaceuticals, Inc., Dermira, Exelixis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New York, NY on Wednesday, February 27, 2019 at 11:00 a.m., ET. An audio webcast of the presentation will be available live. You can access ...

Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its ...

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks undervalued by a bit more than 10% relative to historical avera...

Introduction - good things may be happening here I stopped trading or commenting on Alexion ( ALXN ) in the first half of 2017, when there were countless uncertainties. ALXN was around $110 and was sold at a small loss. ALXN closed Wednesday at $125.18, lagging the market ( SPY ) and a major...

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...